TIDE Project: Biomarker Discovery for Chronic Tinnitus Diagnosis
Completed
Conditions studied: Tinnitus
In brief
Research in clinical neuroscience is founded on the conviction that a better understanding of tinnitus related changes of brain function will improve our ability to diagnose and treat tinnitus. Although considerable advances have been made in understanding the mechanisms of tinnitus, the clinical management of tinnitus remains largely based on a 'trial and error' approach. The identification and validation of a biomarker for tinnitus is thought to be the crucial step in the development of a personalized approach to the diagnosis and treatment of tinnitus. The overarching goal of this study is to incorporate advanced technologies to provide an objective, data-driven, personalized approach to the diagnosis of chronic tinnitus. This should lead to a clinically applicable tool that can be widely and easily used.
Key facts
- Study ID
- NCT06520865
- Run by
- University of Regensburg
- People needed
- 560
- Starts
- 2024-08-01
- Expected to finish
- 2025-11-30
- Last updated by the study team
- 2026-03-24
Who can join
Age: 18 and older, up to 70. Sex: any. Healthy volunteers: accepted.
You may qualify if…
- (1) for tinnitus cases: a diagnosis of chronic and constant tinnitus (for at least 6 months based on history)
- (2) for controls: never experienced tinnitus
- (3) age 18 -70;
- (4) ability to understand and consent to the research;
- (5) ability to participate (hearing ability);
- (6) MoCa Test ≥ 26;
- (7) hyperacusis questionnaire score < 27;
You may not qualify if…
- (1) objective tinnitus; heartbeat-synchronous tinnitus as primary complaint;
- (2) otosclerosis; acoustic neuroma or other relevant ear disorders with fluctuating hearing;
- (3) acute ear nose and throat infections (acute otitis media, otitis externa, acute sinusitis);
- (4) Meniere's disease or similar syndromes;
- (5) vestibular migraine;
- (6) serious internal, neurological or psychiatric conditions;
- (7) epilepsy or other CNS disorders (brain tumor, encephalitis);
- (8) clinically relevant drug, medication or alcohol abuse up to 12 weeks before study start;
- (9) change in anti-depressants/drugs ≤ 2 weeks
- (10) missing written informed consent
- (11) severe hearing loss - inability to communicate properly in the course of the study;
- (12) one deaf ear;
Where it is running
- University of Illinois — Champaign, Illinois, United States
- University of Texas — Austin, Texas, United States
- Brai3n - Research center for Advanced, International, Innovative and Interdisciplinary Neuromodulation — Ghent, Belgium
- University of Tuebingen — Tübingen, Baden-Wurttemberg, Germany
- Center of Neuromodulation - Psychiatry und Psychotherapie der Universität Regensburg am Bezirksklinikum — Regensburg, Bavaria, Germany
- Trinity College Dublin — Dublin, Ireland
- OST - Eastern Switzerland University of Applied Sciences — Sankt Gallen, Switzerland
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.